Loading...
OTCM
ADYX
Market cap0kUSD
Sep 11, Last price  
0.00USD
Name

Adynxx Inc

Chart & performance

D1W1MN
OTCM:ADYX chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-34.66%
Revenues
0
0000001,448,6691,319,2971,832,2341,228,6741,797,7454,786,13115,040,92916,294,0002,019,0002,216,0000000
Net income
0
-1,103,670-1,435,613-2,813,602-4,654,499-4,438,197-3,667,547-763,806-3,098,053-13,853,203-4,905,335-21,976,882-25,445,435-26,017,000-28,243,000-25,707,000-8,417,0000000
CFO
0
-1,022,501-1,364,209-1,332,440-1,422,509-1,895,400-1,984,149-1,174,819-1,713,596-2,196,825-1,966,093-4,769,039-13,291,459-21,622,000-18,335,000-10,672,000-9,710,0000000
Dividend
Apr 18, 20190.175 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.

Key people

Dennis Podlesak
Chairman of the Board
Rick Orr
Chief Executive Officer, Principal Financial Officer, Director · since 2019
Julien Mamet
Chief Scientific Officer, Director · since 2019
Donald Manning
Chief Medical Officer · since 2019
Stan Abel
Director · since 2019
Gregory Flesher
Director · since 2019
Matthew Ruth
Director · since 2019
Eckard Weber
Director · since 2019
URL
https://ir.adynxx.com/
IPO date
Oct 12, 1998
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT